Wednesday, August 3, 2016

BRIEF-Ocular therapeutix says FDA issued a letter noting 1 exception that relates to proposed process for Dextenza

* Provides update on NDA for Dextenza for the treatment of

post-surgical ocular pain

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)